Erin K. Spengler, David E. Kleiner, Robert J. Fontana – 23 June 2016 – Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table ).

Dae Joong Kang, Naga S. Betrapally, Siddhartha A. Ghosh, R. Balfour Sartor, Phillip B. Hylemon, Patrick M. Gillevet, Arun J. Sanyal, Douglas M. Heuman, Daniel Carl, Huiping Zhou, Runping Liu, Xiang Wang, Jing Yang, Chunhua Jiao, Jeremy Herzog, H. Robert Lippman, Masoumeh Sikaroodi, Robert R. Brown, Jasmohan S. Bajaj – 23 June 2016 – The mechanisms behind the development of hepatic encephalopathy (HE) are unclear, although hyperammonemia and systemic inflammation through gut dysbiosis have been proposed.

Richard A. Rosencrantz, Tiangui Huang, Pierre‐Yves Sonke, Deepali Tewari, Praveen N. Chander – 23 June 2016

Erin K. Spengler, David E. Kleiner, Robert J. Fontana – 23 June 2016 – Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table ).

Hao Zhang, Zheng Xing, Saravana Kumar Kailasam Mani, Brigitte Bancel, David Durantel, Fabien Zoulim, Elizabeth J. Tran, Philippe Merle, Ourania Andrisani – 23 June 2016 – Chronic hepatitis B virus (HBV) infection is a major factor in hepatocellular carcinoma (HCC) pathogenesis by a mechanism not yet understood. Elucidating mechanisms of HBV‐mediated hepatocarcinogenesis is needed to gain insights into classification and treatment of HCC.

Jonathan Chung‐Fai Leung, Thomson Chi‐Wang Loong, Jeremy Lok Wei, Grace Lai‐Hung Wong, Anthony Wing‐Hung Chan, Paul Cheung‐Lung Choi, Sally She‐Ting Shu, Angel Mei‐Ling Chim, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong – 23 June 2016 – Although nonalcoholic fatty liver disease (NAFLD) is closely linked to obesity, around 10%‐20% of nonobese Americans and Asians still develop NAFLD. Data on this special group are limited. We therefore studied the severity and clinical outcomes of nonobese NAFLD patients. Consecutive NAFLD patients who underwent liver biopsy were prospectively recruited.

Damien Ulveling, Sigrid Le Clerc, Aurélie Cobat, Taoufik Labib, Josselin Noirel, Vincent Laville, Cédric Coulonges, Wassila Carpentier, Bertrand Nalpas, Markus H.

22 June 2016

22 June 2016

22 June 2016